ZOLEDRONIC ACID
Clinical safety rating: avoid
Contraindicated (not allowed)
Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway.
| Metabolism | Zoledronic acid is not metabolized and is excreted unchanged by the kidney via glomerular filtration and tubular secretion. |
| Excretion | Primarily renal (30-40% unchanged in urine over 24h, accounting for ~50% of total clearance); negligible biliary or fecal elimination (<1%). |
| Half-life | Terminal half-life is approximately 146 hours (6 days), reflecting slow release from bone; clinical effect persists beyond this due to prolonged binding to hydroxyapatite. |
| Protein binding | ~28% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | 0.13 L/kg (range 0.1-0.2 L/kg), indicating limited distribution to peripheral tissues; extensive binding to bone mineral surfaces. |
| Bioavailability | Oral bioavailability is negligible (<1% due to high polarity and poor absorption); only administered intravenously. |
| Onset of Action | IV: Onset within 24-48 hours for reduction of bone resorption markers; maximal effect on serum calcium in hypercalcemia occurs within 4-7 days. |
| Duration of Action | Single dose suppresses bone resorption for up to 12 months; repeat dosing at approved intervals (e.g., annually for osteoporosis) maintains effect. |
5 mg intravenously over at least 15 minutes once yearly for Paget disease or osteoporosis; 4 mg intravenously over at least 15 minutes every 3-4 weeks for hypercalcemia of malignancy or multiple myeloma/bone metastases.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated if CrCl <35 mL/min. For CrCl 35-60 mL/min: no dose adjustment for osteoporosis; for malignancy, consider risk/benefit. CrCl <35 mL/min: use not recommended. Monitor serum creatinine before each dose. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment. Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Safety and efficacy not established in children; use only in clinical trials or specific conditions like osteogenesis imperfecta. Dosing typically 0.05-0.1 mg/kg intravenously over at least 30 min, frequency based on study protocol. Off-label use with caution. |
| Geriatric use | No specific dose adjustment based on age alone; renal function must be assessed (CrCl) and dose adjusted accordingly. Monitor for renal toxicity, hypocalcemia, and atrial fibrillation risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Nephrotoxic drugs may increase risk of renal impairment Can cause renal impairment and osteonecrosis of the jaw.
| Breastfeeding | Zoledronic acid is excreted in human milk at low levels; M/P ratio not established. Due to potential for bone growth suppression, breastfeeding is not recommended during therapy. |
| Teratogenic Risk | Zoledronic acid is pregnancy category D. First trimester: Potential for skeletal abnormalities based on animal studies. Second and third trimesters: Risk of fetal hypocalcemia and skeletal retardation due to placental transfer and bone remodeling inhibition. Avoid use unless benefit outweighs risk. |
■ FDA Black Box Warning
Zoledronic acid is not recommended for use in patients with severe renal impairment (CrCl <35 mL/min) due to increased risk of renal failure. Acute renal failure may occur, especially in patients with pre-existing renal dysfunction or dehydration.
| Common Effects | Nausea Headache Dizziness Itching Insomnia difficulty in sleeping Rash Genital itching Vaginal inflammation Phlebitis Injection site reactions pain swelling redness |
| Serious Effects |
["Hypocalcemia","Creatinine clearance <35 mL/min","Pregnancy (category D)","Lactation","Hypersensitivity to zoledronic acid or any component of the formulation"]
| Precautions | ["Renal toxicity: Monitor renal function before and during therapy; avoid in severe renal impairment (CrCl <35 mL/min).","Acute phase reaction: Transient flu-like symptoms (fever, myalgia, arthralgia) may occur, especially with first dose.","Osteonecrosis of the jaw (ONJ): Risk factors include invasive dental procedures, cancer, poor oral hygiene; perform dental exam before treatment.","Atypical femur fractures: Subtrochanteric and diaphyseal fractures reported; evaluate if thigh or groin pain occurs.","Hypocalcemia: Correct hypocalcemia and vitamin D deficiency before initiating therapy; monitor calcium levels.","Severe bone, joint, and muscle pain: May occur; consider discontinuation if symptoms persist."] |
Loading safety data…
| Fetal Monitoring |
| Monitor serum calcium, magnesium, phosphate, and creatinine in mother. Fetal ultrasound for skeletal development if exposure occurs. Neonatal monitoring for hypocalcemia and electrolyte disturbances. |
| Fertility Effects | Zoledronic acid may impair fertility in males and females based on animal studies (reduced fertility and fetal loss). Clinical data in humans limited; consider potential for ovarian or testicular toxicity. |